Vincerx Pharma, Inc. (VINC)
| Market Cap | 36.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -65.84M |
| Shares Out | 21.19M |
| EPS (ttm) | -2.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 334,062 |
| Open | 1.66 |
| Previous Close | 1.64 |
| Day's Range | 1.63 - 1.74 |
| 52-Week Range | 1.26 - 18.43 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | 13.46 (+682.6%) |
| Earnings Date | Aug 10, 2022 |
About VINC
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc.... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for VINC stock is "Buy." The 12-month stock price forecast is 13.46, which is an increase of 682.56% from the latest price.
News
Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Continue to execute on priority indications for VIP152; recently issued the INN enitociclib
Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hema...
Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation
Analysts Cuts Price Target On This Small Cap But Remain Bullish
Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ: VINC) to $4 from $11 and kept a Buy rating on the shares. The company announced a strategic update to focus on its...
Vincerx Pharma Provides Key Strategic Update
Prioritizing Phase 1b VIP152 studies to focus on double-hit DLBCL and CLL
Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Company to present poster on VIP152 at upcoming European Hematology Association Annual Meeting
Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malig...
VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies
Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
Dosed first patient in VIP152 and pembrolizumab combination arm of study VNC-152-101
Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
PALO ALTO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradig...
Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
PALO ALTO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm...
Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential of Small Molecule-Drug Conjugate VIP236...
VIP236 is a first-in-class anticancer agent, optimized using Vincerx's proprietary modular bioconjugation platform to target aggressive tumors
Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chr...
PALO ALTO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm...
Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematolo...
VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease
Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Larg...
PALO ALTO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm...
Vincerx Pharma Hosting Key Opinion Leader Webinar on VIP152 Data Presented at the American Society of Hematology Annu...
PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm...
Vincerx Pharma Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
Advancing Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors
Vincerx Pharma Announces Presentations at the American Society of Hematology Annual Meeting
PALO ALTO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm...
Vincerx Pharma Announces $50 Million Private Placement
Strengthened financial position extends expected cash runway into 2023 Strengthened financial position extends expected cash runway into 2023
Vincerx Pharma Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
First patient dosed in Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors
4 Stocks With CEO Buys in the Past Month
According to the CEO Buys Screen, a Premium All-in-One Screener template, four stocks that had at least three insider buys including the CEO during the past month are REV Group Inc. ( REVG , Financial),...
UPDATE -- Vincerx Pharma Presents Clinical Data on VIP152, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymp...
VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting
Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at AS...
VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting
Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggress...
First patient dosed by Vincerx marks significant milestone in Company's development First patient dosed by Vincerx marks significant milestone in Company's development
Vincerx Pharma to Participate in the Jefferies Virtual Healthcare Conference
PALO ALTO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-...
Vincerx Pharma Reports First Quarter 2021 Financial Results and Provides a Corporate Update
Phase 1b dose escalation study of VIP152 in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021
Vincerx Pharma Announces FDA Clearance of IND for Phase 1b Study of VIP152 in Chronic Lymphocytic Leukemia and Richte...
Dose escalation study in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021